** Shares of medtech firm Firefly Neuroscience AIFF.O rise 24% to $2 premarket

** Co says its AI tool aims to identify types of ADHD — a condition that can affect focus, impulse control or both — using brain scans instead of symptom checklists

** Adds that tool uses brain scans from its FDA-cleared Evoke System to study electrical activity in the brain

** Says platform is trained on more than 191,000 brain scans, the largest such database

** The technology could help doctors tailor treatments, as different types of ADHD respond differently to medication, and track whether they are working over time, co says

** YTD, shares nearly doubled in value vs. a ~67% decline in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))